HC Wainwright Issues Negative Outlook for UNCY Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Investment analysts at HC Wainwright lowered their Q1 2025 EPS estimates for Unicycive Therapeutics in a research note issued on Tuesday, April 1st. HC Wainwright analyst E. Arce now expects that the company will post earnings of ($0.08) per share for the quarter, down from their previous forecast of ($0.07). HC Wainwright currently has a "Buy" rating and a $7.50 target price on the stock. The consensus estimate for Unicycive Therapeutics' current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Unicycive Therapeutics' Q1 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.35) EPS, FY2025 earnings at ($0.35) EPS, FY2026 earnings at $0.92 EPS, FY2026 earnings at $0.92 EPS, FY2027 earnings at $1.98 EPS, FY2027 earnings at $1.98 EPS, FY2028 earnings at $1.19 EPS and FY2029 earnings at $1.34 EPS.

Unicycive Therapeutics Stock Up 7.4 %

Shares of Unicycive Therapeutics stock traded up $0.03 on Friday, reaching $0.51. The company's stock had a trading volume of 357,828 shares, compared to its average volume of 1,436,661. The stock has a 50-day moving average price of $0.58 and a 200-day moving average price of $0.57. Unicycive Therapeutics has a 52-week low of $0.20 and a 52-week high of $1.39. The company has a market capitalization of $60.45 million, a P/E ratio of -0.52 and a beta of 2.15.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last posted its earnings results on Thursday, March 27th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.13).

Institutional Trading of Unicycive Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of UNCY. Northern Trust Corp raised its position in Unicycive Therapeutics by 142.4% in the fourth quarter. Northern Trust Corp now owns 58,181 shares of the company's stock valued at $46,000 after purchasing an additional 34,183 shares during the period. Virtu Financial LLC boosted its holdings in Unicycive Therapeutics by 566.8% in the third quarter. Virtu Financial LLC now owns 73,975 shares of the company's stock valued at $30,000 after purchasing an additional 62,881 shares during the period. XTX Topco Ltd purchased a new position in Unicycive Therapeutics in the third quarter worth approximately $29,000. Geode Capital Management LLC increased its holdings in Unicycive Therapeutics by 30.3% in the fourth quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock valued at $417,000 after buying an additional 122,089 shares during the last quarter. Finally, Acuta Capital Partners LLC boosted its holdings in shares of Unicycive Therapeutics by 16.4% in the 4th quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company's stock valued at $1,829,000 after buying an additional 323,801 shares in the last quarter. 40.42% of the stock is currently owned by hedge funds and other institutional investors.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.